← Viking Therapeutics, Inc. (VKTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Viking Therapeutics, Inc. (VKTX)
Pharmaceutical Preparations · market cap $4.9B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-28 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Viking Therapeutics (VKTX) is a clinical-stage pharmaceutical company with zero revenue and a market cap of ~$4.5B, built almost entirely on the optionality of VK2735, a Phase 3 weight-loss candidate. The company carries ~$118M in cash against a reported 3.1-month runway, creating acute near-term financing pressure. The pipeline also includes VK2809 (Phase 2, NASH) and VK5211 (Phase 2, hip fractures), but neither is near a value-inflecting readout.
The catalyst path
- 2026-10-28 (est.)Earningsimp 5/10
- 2026-10-31Phase 3 · VK2735imp 6/10
- 2027-07-01 (est.)Phase 3 · VK2735imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VK2809 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| VK2735 | Phase 3 | Weight Loss |
| VK5211 | Phase 2 | Hip Fractures |
Price & technical context
3-month
-13.0%
6-month
+0.2%
12-month
+26.3%
52-wk range
$26.28–$42.13
vs 50-day MA
-2.9%
vs 200-day MA
-1.9%
Realized vol
66.4%
Max drawdown
-74.4%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VKTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.